ArticleArthritis research & therapy2026
Elevated ST2
Article in Arthritis research & therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundInterstitial lung disease (ILD) represents a significant extra-articular complication associated with rheumatoid arthritis (RA), contributing substantially to the morbidity and mortality observed in affected patients. Despite its clinical relevance, the underlying mechanisms driving the pathogenesis of RA-ILD remain poorly understood, necessitating further investigation into the immunological factors that may play a role in this condition.
methodsThis study aimed to elucidate the role of ST2
resultsHistopathological assessment confirmed that the composite model exhibited exacerbated lung inflammation and fibrosis. Notably, flow cytometry revealed a marked expansion of ST2
conclusionThese results highlight the potential involvement of the IL-33/ST2 axis in mediating a pathogenic Tregs response characterized by AREG production, thereby linking systemic autoimmunity to the progression of lung fibrosis in RA-ILD. Importantly, this study identifies the IL-33/ST2/AREG axis and ST2
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.